An interventional study of Fecal Microbiota Transplantation and Placebo in Acute Pancreatitis, sponsored by Changhai Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Changhai Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Pancreatitis by Changhai Hospital — 7 open to participants now, 7 under way, none of them phase 3. Pancreatitis · Changhai Hospital.
Among the 16 studies in Pancreatitis by Changhai Hospital, this one is one of 2 that started in 2026, is one of 6 with no phase, and was the 16th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →7 of the 16 studies in Pancreatitis by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:
Changhai Hospital · Sites in China
Ages 18–80
Changhai Hospital · Sites in China
Ages 18–85
Changhai Hospital · Sites in China
Ages 18+
Changhai Hospital · Sites in China
Ages 18–70
Changhai Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 533 across the 8 interventional studies, 1,549 across the 8 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.
2 of the studies in Pancreatitis by Changhai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07153809Changhai HospitalFecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis | 2026-12-31 |
| NCT07464392Changhai HospitalFMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis | 2027-07-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Pancreatitis by Changhai Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether fecal microbiota transplantation (FMT) works to prevent infections complications in patients in the late phase of moderately severe or severe acute pancreatitis.
This multicenter, randomized, double-blind, placebo-controlled trial evaluates whether fecal microbiota transplantation (FMT) works to prevent infectious complications in patients in the late phase of moderately severe and severe acute pancreatitis.
Approximately 150 eligible participants will be enrolled across 12 centers in China and randomly assigned to receive either FMT plus standard treatment or placebo plus standard treatment. The intervention is administered via nasojejunal tube once daily for five consecutive days.
The study will assess infection-related outcomes, organ function, nutritional status, gastrointestinal function, gut microbiota changes, need for additional interventions or surgery, mortality, antibiotic use, and healthcare utilization. Exploratory analyses will investigate inflammatory and immune responses, and explore a predictive model based on baseline gut microbiota characteristics and clinical indicators.
All analyses will follow the intention-to-treat principle, aiming to inform better treatment choices and ultimately improve patient outcomes and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fecal microbiota transplantation (FMT) liquid, 100 mL , administered via nasojejunal tube, once daily for 5 consecutive days, plus standard treatment.
Biological: Fecal Microbiota Transplantation
Sterile saline (0.9% sodium chloride) solution, 100 mL, administered via nasojejunal tube, once daily for 5 consecutive days, plus standard treatment. Placebo is identical in appearance to FMT to maintain blinding.
Other: Placebo
Fecal microbiota transplantation (FMT) liquid is a biological intervention consisting of processed and standardized human fecal microbiota from healthy donors, suspended in sterile saline with cryoprotectant.
Sterile saline (0.9% sodium chloride) solution, packaged identically to FMT liquid with opaque materials to maintain blinding, contains no active components and serves as a placebo control.
Incidence of Infectious Complications
Proportion of participants developing any of the following infectious complications: Infected pancreatic necrosis Bacteremia Pneumonia Urosepsis Infected ascites All infections are weighted equally; multiple infections in the same patient are counted as a single endpoint.
Time frame: Within 30 days after enrollment
Incidence of Infectious Complications
Proportion of participants developing any infectious complications (as defined in the primary outcome)
Time frame: Within 90 days after enrollment
Organ Failure
Incidence of organ failure assessed by Sequential Organ Failure Assessment (SOFA) score and modified Marshall score.
Time frame: From enrollment to hospital discharge (up to 90 days)
Enteral Nutrition Caloric Intake
Daily enteral nutrition caloric intake assessed to evaluate adequacy of nutritional support. Reported in kcal/kg/day.
Time frame: From enrollment to hospital discharge (up to 90 days)
NUTRIC Score
Nutrition Risk in Critically Ill (NUTRIC) score used to assess nutritional risk in ICU patients. Scores range from 0 to 10; higher scores indicate greater nutritional risk.
Time frame: From enrollment to hospital discharge (up to 90 days)
Subjective Global Assessment (SGA)
Nutritional status assessed by Subjective Global Assessment. Patients are classified as: A (well-nourished), B (moderately malnourished), or C (severely malnourished).
Time frame: Baseline, Day 30, Day 60, Day 90
Serum Nutritional Protein Markers
Serum levels of hemoglobin, albumin, and total protein measured to assess nutritional and metabolic status. Reported in g/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Prealbumin
Serum levels of prealbumin measured to assess nutritional and metabolic status. Reported in mg/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Electrolyte Levels
Serum levels of phosphorus and magnesium measured to assess electrolyte balance. Reported in mmol/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Body Mass Index (BMI)
BMI calculated from measured height (meters) and weight (kilograms) to assess nutritional status. Reported in kg/m².
Time frame: From enrollment to 90-day follow-up
Gastrointestinal Symptom Rating Scale (GSRS)
Gastrointestinal symptoms assessed using the simplified GSRS. Scores range from 0 to 42; higher scores indicate more severe symptoms.
Time frame: From enrollment to 90-day follow-up
Incidence of Gastrointestinal Adverse Events
Daily monitoring from randomization to discharge of the following events: vomiting (≥1 episode/day), abdominal distension (assessed by daily abdominal circumference measurement), diarrhea (Bristol type 6-7 and ≥3 times/day), intestinal perforation, and abdominal bleeding. Reported in percentage of participants (%).
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Total Bile Acids Level
Serum total bile acids measured to assess enterohepatic circulation and gut microbiota-mediated bile acid metabolism. Reported in μmol/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Diamine Oxidase (DAO) Level
Serum diamine oxidase level measured as a biomarker of intestinal mucosal barrier integrity and enterocyte damage. Reported in U/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Endotoxin Level
Serum endotoxin level measured to assess intestinal permeability and the degree of bacterial translocation across the gut barrier. Reported in EU/mL.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum D-Lactate Level
Serum D-lactate level measured as a biomarker of intestinal mucosal permeability and bacterial overgrowth in the gastrointestinal tract. Reported in μmol/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Gut Microbiota Changes
Changes in fecal microbiota composition and diversity assessed by metagenomic sequencing.
Time frame: Baseline, Day 7, Day 30, Day 90
Need for Additional Interventions or Surgery
Proportion of participants requiring additional invasive interventions after FMT treatment.
Time frame: From treatment initiation to 90-day follow-up
Mortality
All-cause mortality.
Time frame: From enrollment to 90-day follow-up
Antibiotic Utilization
Proportion of participants receiving antibiotics and duration of antibiotic use.
Time frame: From hospital admission to 90-day follow-up
Hospital Length of Stay
Duration of hospitalization (days).
Time frame: From enrollment to hospital discharge (up to 90 days)
Hospital Total Costs
Total hospitalization costs incurred during the index admission, including costs related to medication, procedures, nursing care, and ICU stay. Reported in CNY (Chinese Yuan).
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Cytokine Levels
Serum levels of IL-6, IL-8, IL-10, and TNF-α measured to assess systemic inflammatory response. Reported in pg/mL.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum C-Reactive Protein (CRP) Level
Serum CRP level measured as a marker of systemic inflammation. Reported in mg/L.
Time frame: From enrollment to hospital discharge (up to 90 days)
Serum Procalcitonin (PCT) Level
Serum PCT level measured as a marker of infection and inflammatory response. Reported in ng/mL.
Time frame: From enrollment to hospital discharge (up to 90 days)
CD4+ and CD8+ T Cell Counts
Peripheral blood CD4+ and CD8+ T lymphocyte counts measured to assess cellular immune function.
Time frame: From enrollment to hospital discharge (up to 90 days)
Immune Cell Indices
Neutrophil CD64 index and CD4+/CD8+ ratio assessed to evaluate immune activation and balance.
Time frame: From enrollment to hospital discharge (up to 90 days)
Predictive Model Performance for Infectious Complications and FMT Response
Predictive performance of a model based on baseline gut microbiota characteristics and clinical parameters to identify patients at high risk for infectious complications and to predict individual response to FMT treatment, evaluated by the area under the receiver operating characteristic curve (AUC-ROC).
Time frame: From enrollment to 90-day follow-up
Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.
Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 15 months is below that.
Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.